1. PP2A as a potential therapeutic target for breast cancer: Current insights and future perspectives
   Yalong Qi et al, 2024, Biomedicine & Pharmacotherapy CrossRef
2. CIP2A as a Key Regulator for AKT Phosphorylation Has Partial Impact Determining Clinical Outcome in Breast Cancer
   Melani Luque et al, 2022, Journal of Clinical Medicine CrossRef
3. Arctigenin inhibits triple-negative breast cancers by targeting CIP2A to reactivate protein phosphatase 2A
   Qiuyue Huang et al, 2017, Oncology Reports CrossRef
4. PP2A as the Main Node of Therapeutic Strategies and Resistance Reversal in Triple-Negative Breast Cancer
   Henan Zhao et al, 2017, Molecules CrossRef
5. Cucurbitacin B Induces the Lysosomal Degradation of EGFR and Suppresses the CIP2A/PP2A/Akt Signaling Axis in Gefitinib-Resistant Non-Small Cell Lung Cancer
   Pengfei Liu et al, 2019, Molecules CrossRef
6. Activation of cancerous inhibitor of PP2A (CIP2A) contributes to lapatinib resistance through induction of CIP2A-Akt feedback loop in ErbB2-positive breast cancer cells
   Ming Zhao et al, 2017, Oncotarget CrossRef